Staph aureus bacteremia: new guideline will change management

You heard it here first, probably

Staphylococcus aureus is a particularly virulent gram-positive bacterium that lives on the skin or mucous membranes of about one-third of people, causing no harm. When S. aureus gains access to the bloodstream, however, it can become life-threatening within a short period.

Staphylococcus aureus bacteremia management (Review)

Worse, S. aureus is adapted to adhere to and grow on deep-seated tissues or prosthetics, producing biofilms, vegetations, or abscesses. These can be difficult to detect and require several weeks or months of antibiotics (and often device removal) to eradicate. Inadequate treatment courses can result in even more prolonged infections and poor outcomes.

Because of the difficulty in ruling out so-called metastatic foci of staph infection, infectious diseases specialist guidance has historically been very conservative, recommending prolonged treatment courses for any patient not considered at very low risk for persistent infection. (Patients with no risk factor or evidence of metastatic foci were generally prescribed 14 days of antibiotics.)

But providing four to six weeks of antibiotics, usually in the outpatient setting, creates logistical headaches for health systems and enormous inconvenience for patients. It’s always been an open secret that many of these patients don’t benefit from the long courses—and that a few will even be harmed—but there’s been no way to confidently identify or advise whose course can be shortened.

There’s reason to believe this situation may soon change.

Wait, Give That Back

In July 2026, a leading infectious diseases specialty society soft-launched or prematurely released a new guideline on staphylococcal bacteremia. The documents were withdrawn and the links redirected to dead-end pages. The guideline is now listed as “In Development,” and the manuscripts are unavailable on the relevant websites.

Search engines and web scrapers index newly posted content almost instantly these days, though, with the escaped content then rendered into various semi-accessible formats, so it’s possible to guess at what the contours of the new guidance will be.

We should presume the information was withdrawn for good reasons, so the following is speculative, informational only, and should not be used to guide clinical practice until it’s published in a peer-reviewed journal.

Downgrading the “risk = disease” mindset

By the strict letter of the 2011 guidelines for MRSA bacteremia (which have guided treatment of MSSA as well), any patient at risk for deep S. aureus infection is considered as if they have one. That has included anyone with: